Results from phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer

Saved in:
Bibliographic Details
Published inJournal of Clinical Oncology Vol. 37; p. 325
Main Authors Yusuke Hashimoto, Makoto Ueno, Masafumi Ikeda, Maki Tanaka
Format Journal Article
LanguageJapanese
Published American Society of Clinical Oncology (ASCO) 01.02.2019
Online AccessGet full text

Cover

More Information
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2019.37.4_suppl.325